In a report issued on June 30, Joel Beatty from Robert W. Baird reiterated a Buy rating on Blueprint Medicines (BPMC – Research Report), with a price target of $96.00. The company's shares closed last Friday at $49.93, close to its 52-week low of $43.46. According to TipRanks.com, Beatty is a 3-star analyst with an average return of 1.9% and a 49.4% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, and BioMarin Pharmaceutical. Currently, the analyst consensus on Blueprint Medicines is a Moderate Buy with an average price target of $79.78, a 59.4% upside from current levels.
https://www.tipranks.com/news/blurbs/blueprint-medicines-bpmc-gets-a-buy-rating-from-robert-w-baird?utm_source=advfn.com&utm_medium=referral
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Blueprint Medicines Charts.
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Blueprint Medicines Charts.